Equity Details
Price & Market Data
Price: $1.92
Daily Change: -$0.024 / 1.25%
Daily Range: $1.87 - $1.97
Market Cap: $27,540,544
Daily Volume: 61,148
Performance Metrics
1 Week: -10.70%
1 Month: -10.28%
3 Months: -20.66%
6 Months: -79.83%
1 Year: -72.05%
YTD: -33.10%
About Tempest Therapeutics, Inc. (TPST)
Discover the market presence of Tempest Therapeutics, Inc. (TPST). Price: 1.92, daily change: -$0.024 / 1.25%. Market cap: 27,540,544. Performance across all periods for a clear financial view.
Company Details
Employees: 4
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.